腺相关病毒的替代受体
Bijay P Dhungel1, Hua Xu2, Rajini Nagarajah3
1School of Medical Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, NSW 2006, Australia; Cancer & Gene Regulation Laboratory Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia; Centre for Rare Diseases & Gene Therapy Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia.
Cell
|July 15, 2025
概括
研究人员发现了一种新的腺相关病毒 (AAV) 受体,AAVR2 (碳氧酶D),它为基因疗法提供了一条新途径. 这一发现可能有助于减少与高AAV载体剂量相关的毒性.
科学领域:
- 分子生物学
- 基因治疗
- 病毒学
背景情况:
- 腺相关病毒 (AAV) 载体对于治疗遗传疾病至关重要.
- 高剂量的AAV载体可能导致毒性,限制其临床应用.
研究的目的:
- 识别已知的AAVR之外的其他AAV受体.
- 通过新型受体阐明AAV转导的机制.
- 制定减少AAV载体剂量相关毒性的策略.
主要方法:
- 低温电子显微镜 (低温电子显微镜) 用于描述AAV受体相互作用.
- 生物化学测定以确认AAV8囊和AAVR2之间的直接结合.
- 用AAV囊生物工程改变受体结合.
- 在体内研究涉及过度表达AAVR2以增强转导.
主要成果:
- 确定了AAVR2 (carboxypeptidase D) 作为一个独特的AAV受体.
- AAVR2通过AAVR独立的途径调节E类AAV (例如AAV8) 的转导.
- 确定了AAV8素与AAVR2的碳氧酶类域1的直接结合.
- 证明了AAV2参与的AAV囊的成功生物工程.
- 通过过度表达AAVR2显示增强体内AAV转导.
结论:
- AAVR2代表了特定的AAV血清型的新进入受体.
- 了解AAVR2介导的进入为基因治疗载体的开发提供了新的途径.
- 这一发现为减轻AAV基因疗法的剂量相关毒性提供了潜在的解决方案.
相关概念视频
01:31Adrenergic Receptors: ɑ Subtype
1.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.9K
01:27Adrenergic Receptors (Adrenoceptors): Classification
3.3K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
3.3K
01:26Adrenergic Receptors: β Subtype
2.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.2K